Last update
5/27/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 10 Researches
7.1
USERS' SCORE
Good
Based on 8 Reviews
8.1
Supplement Facts
Serving Size: 1 Veggie Capsule
Amount Per Serving
%DV
Calcium (from tricalcium phosphate and calcium stearate in Serrateric™)
29 mg
2%
Serrapeptase Enzyme (from Serratio sp.)
40,000 SPU**
†
Nattokinase (from fibrinase enzyme)
2,000 FU***
†
Top Medical Research Studies
0
We examined how nattokinase affects the progression of atherosclerosis and related biomarkers in a double-blind trial involving 265 participants averaging 65 years old, who had no cardiovascular disease. Participants received either nattokinase or a placebo for three years.
Our findings revealed that nattokinase had no significant effect on subclinical atherosclerosis progression, blood pressure, or other laboratory measures. This indicates that nattokinase may not provide the anticipated cardiovascular benefits in healthy individuals at low risk for heart disease.
Our findings revealed that nattokinase had no significant effect on subclinical atherosclerosis progression, blood pressure, or other laboratory measures. This indicates that nattokinase may not provide the anticipated cardiovascular benefits in healthy individuals at low risk for heart disease.
Read More
8
We explored how nattokinase (NK), a strong clot-buster, can be delivered effectively using NK-conjugated magnetite nanoparticles (NK-MNPs). These nanoparticles were designed to release NK directly at the site of a thrombus and showed promising results in sustained release and thrombolytic potential.
After encapsulating NK, the nanoparticles demonstrated a successful release rate and maintained their efficacy even after storage. However, while the findings are encouraging, they suggest that NK-MNPs may not be a definitive solution but instead a promising avenue for further research into treating thrombus-related diseases.
After encapsulating NK, the nanoparticles demonstrated a successful release rate and maintained their efficacy even after storage. However, while the findings are encouraging, they suggest that NK-MNPs may not be a definitive solution but instead a promising avenue for further research into treating thrombus-related diseases.
Read More
9.5
We explored an innovative approach to treating blood clots using specially designed magnetic nanorobots that deliver nattokinase directly to targeted areas. These tiny robots are not only able to navigate through blood vessels but also use a combination of magnetic fields to break down clots effectively.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
Read More
Most Useful Reviews
9
Effective for Long Covid
1 people found this helpful
From day one, I noticed positive effects of this supplement on Long Covid symptoms. It appears to help dissolve fibroid clots within the cardiovascular system. Although the initial discomfort was concerning, it clearly indicated that the supplement was working. After a week, I experienced significant improvements in my overall well-being. I’d highly recommend it to others facing similar issues.
Read More
9
Highly effective
1 people found this helpful
I wholeheartedly rate Nattoin with five stars for its effectiveness in addressing cardiovascular disease. Friends with atheromatous plaques should definitely give it a try; it truly works.
Read More
7
Normalizes pressure
28 people found this helpful
I firmly believe in enzyme therapy and had previously used enzymes from another brand. After a week of taking one capsule daily, I added another and felt my body “tighten up” and lighter. My blood pressure normalised after three weeks; I aimed to improve my cardiovascular system and clear my vessels due to historically high cholesterol.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 10 Researches
7.1
- All Researches
9.5
We explored an innovative approach to treating blood clots using specially designed magnetic nanorobots that deliver nattokinase directly to targeted areas. These tiny robots are not only able to navigate through blood vessels but also use a combination of magnetic fields to break down clots effectively.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
Read More
8
We examined how a new treatment combining nattokinase with manganese oxide nanozymes might help with acute myocardial infarction, a serious heart condition often caused by blood clots.
Our study revealed that administering this innovative combination through injection significantly improved blood vessel function and decreased heart damage in mice.
The results suggest that these nattokinase-loaded nanozymes could offer a promising strategy to tackle heart attacks effectively, particularly through their antioxidant and thrombolytic properties.
Our study revealed that administering this innovative combination through injection significantly improved blood vessel function and decreased heart damage in mice.
The results suggest that these nattokinase-loaded nanozymes could offer a promising strategy to tackle heart attacks effectively, particularly through their antioxidant and thrombolytic properties.
Read More
8
We explored the effectiveness of a specific strain of Bacillus subtilis in producing nattokinase to enhance fermented milk's health benefits. This probiotic contributed to significant thrombolytic activity, which helps prevent blood clots, a major factor in cardiovascular disease.
Our study demonstrated that fermented milk from B. subtilis could inhibit thrombosis in mice, indicating a promising way to integrate healthy options in our diets. Notably, sensory evaluations revealed that this functional fermented milk was well-accepted, similar to traditional options.
Overall, our findings highlight the potential of B. subtilis JNFE0126-fermented milk as a delicious, healthful alternative that may help reduce cardiovascular risks.
Our study demonstrated that fermented milk from B. subtilis could inhibit thrombosis in mice, indicating a promising way to integrate healthy options in our diets. Notably, sensory evaluations revealed that this functional fermented milk was well-accepted, similar to traditional options.
Overall, our findings highlight the potential of B. subtilis JNFE0126-fermented milk as a delicious, healthful alternative that may help reduce cardiovascular risks.
Read More
8
We explored how nattokinase (NK), a strong clot-buster, can be delivered effectively using NK-conjugated magnetite nanoparticles (NK-MNPs). These nanoparticles were designed to release NK directly at the site of a thrombus and showed promising results in sustained release and thrombolytic potential.
After encapsulating NK, the nanoparticles demonstrated a successful release rate and maintained their efficacy even after storage. However, while the findings are encouraging, they suggest that NK-MNPs may not be a definitive solution but instead a promising avenue for further research into treating thrombus-related diseases.
After encapsulating NK, the nanoparticles demonstrated a successful release rate and maintained their efficacy even after storage. However, while the findings are encouraging, they suggest that NK-MNPs may not be a definitive solution but instead a promising avenue for further research into treating thrombus-related diseases.
Read More
8
Nattokinase-enhanced nanocomposites for thrombolysis
We explored the potential of nattokinase, a promising thrombolytic agent, by creating stable nanocomposites using polylysine dendrimers. Through innovative methods, we ensured that nattokinase was effectively protected from environmental factors, enhancing its stability and activity.
When combined at a 1:30 molar ratio, these nanocomposites demonstrated a remarkable thrombolysis rate, effectively targeting blood clots while minimizing risk of complications. This research indicates that these nanostructures could pave the way for safer and more effective thrombolytic therapies.
When combined at a 1:30 molar ratio, these nanocomposites demonstrated a remarkable thrombolysis rate, effectively targeting blood clots while minimizing risk of complications. This research indicates that these nanostructures could pave the way for safer and more effective thrombolytic therapies.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.1
- All Reviews
- Positive Reviews
- Negative Reviews
9
Effective for Long Covid
1 people found this helpful
From day one, I noticed positive effects of this supplement on Long Covid symptoms. It appears to help dissolve fibroid clots within the cardiovascular system. Although the initial discomfort was concerning, it clearly indicated that the supplement was working. After a week, I experienced significant improvements in my overall well-being. I’d highly recommend it to others facing similar issues.
Read More
9
Highly effective
1 people found this helpful
I wholeheartedly rate Nattoin with five stars for its effectiveness in addressing cardiovascular disease. Friends with atheromatous plaques should definitely give it a try; it truly works.
Read More
7
Normalizes pressure
28 people found this helpful
I firmly believe in enzyme therapy and had previously used enzymes from another brand. After a week of taking one capsule daily, I added another and felt my body “tighten up” and lighter. My blood pressure normalised after three weeks; I aimed to improve my cardiovascular system and clear my vessels due to historically high cholesterol.
Read More
8
Promotes heart health
Doctor's Best, Natto-Seppa is a supplement containing the enzyme Natto, which significantly enhances cardiovascular health. It’s of high quality, with an appropriate dosage. The packaging is convenient, making the capsules easy to swallow, and it aids in maintaining the heart and blood vessel function.
Read More
8
High-quality ingredients
Good quality ingredients beneficial for cardiovascular disease.
Read More
Frequently Asked Questions
9
Effective for Long Covid
1 people found this helpful
From day one, I noticed positive effects of this supplement on Long Covid symptoms. It appears to help dissolve fibroid clots within the cardiovascular system. Although the initial discomfort was concerning, it clearly indicated that the supplement was working. After a week, I experienced significant improvements in my overall well-being. I’d highly recommend it to others facing similar issues.
7
Normalizes pressure
28 people found this helpful
I firmly believe in enzyme therapy and had previously used enzymes from another brand. After a week of taking one capsule daily, I added another and felt my body “tighten up” and lighter. My blood pressure normalised after three weeks; I aimed to improve my cardiovascular system and clear my vessels due to historically high cholesterol.
7.5
Improves blood circulation
I've incorporated Doctor's Best Natto-Serra into my daily routine, and I'm happy with the benefits it offers for cardiovascular health. This 90-capsule bottle supplies a unique combination of nattokinase, known for promoting blood circulation by breaking down fibrin, and serrapeptase, which has anti-inflammatory properties that may help with joint discomfort. Although it can be beneficial for heart health, individual responses vary, so consulting a healthcare provider is wise before starting any new supplement.
9.5
We explored an innovative approach to treating blood clots using specially designed magnetic nanorobots that deliver nattokinase directly to targeted areas. These tiny robots are not only able to navigate through blood vessels but also use a combination of magnetic fields to break down clots effectively.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
In a study involving thrombotic mice, these nattokinase-loaded nanorobots showed an impressive vasculature recanalization rate of 81%. This dual approach of mechanical damage and heat-triggered nattokinase release represents a significant advancement in noninvasive thrombolytic therapy.
7
Nattokinase shows promise in thrombosis
We explored the potential of nattokinase (NK) in tackling cardiovascular disease, particularly its ability to address thrombosis—an ongoing challenge due to the risks of bleeding from traditional treatments.
Our research demonstrated that NK not only alleviated inflammation and oxidative stress in mouse models but also improved kidney health affected by inflammation.
NK showed remarkable effects by inhibiting key inflammatory responses and reducing harmful proteins related to clot formation. While its promise is evident in early research, further studies are necessary to fully understand its benefits for human cardiovascular health.
Our research demonstrated that NK not only alleviated inflammation and oxidative stress in mouse models but also improved kidney health affected by inflammation.
NK showed remarkable effects by inhibiting key inflammatory responses and reducing harmful proteins related to clot formation. While its promise is evident in early research, further studies are necessary to fully understand its benefits for human cardiovascular health.
0
We examined how nattokinase affects the progression of atherosclerosis and related biomarkers in a double-blind trial involving 265 participants averaging 65 years old, who had no cardiovascular disease. Participants received either nattokinase or a placebo for three years.
Our findings revealed that nattokinase had no significant effect on subclinical atherosclerosis progression, blood pressure, or other laboratory measures. This indicates that nattokinase may not provide the anticipated cardiovascular benefits in healthy individuals at low risk for heart disease.
Our findings revealed that nattokinase had no significant effect on subclinical atherosclerosis progression, blood pressure, or other laboratory measures. This indicates that nattokinase may not provide the anticipated cardiovascular benefits in healthy individuals at low risk for heart disease.
8
We investigated the effectiveness of nattokinase in managing carotid artery atherosclerosis and blood lipids over a 26-week treatment with 82 patients in two groups: one receiving nattokinase and the other statins. Both groups showed reductions in carotid plaque size and artery thickness, with the nattokinase group experiencing notably larger reductions.
While both treatments improved lipid profiles, the statin group saw more significant cholesterol reductions. Notably, nattokinase increased HDL levels, showing promise as a potential alternative to statins in managing atherosclerosis, though its effects appear unrelated to lipid changes.
While both treatments improved lipid profiles, the statin group saw more significant cholesterol reductions. Notably, nattokinase increased HDL levels, showing promise as a potential alternative to statins in managing atherosclerosis, though its effects appear unrelated to lipid changes.
References
- Shi Y, Liu C, Gui Y, Guo Y, Zhang Y, et al. A Nattokinase-Loaded Nanozyme for Alleviating Acute Myocardial Infarction via Thrombolysis and Antioxidation. Adv Healthc Mater. 2024. 10.1002/adhm.202402763
- Gao R, Zhang W, Chen X, Shen J, Qin Y, et al. Dual Frequency-Regulated Magnetic Vortex Nanorobots Empower Nattokinase for Focalized Microvascular Thrombolysis. ACS Nano. 2024;18:29492. 10.1021/acsnano.4c04331
- Zhang X, Tong Y, Wang J, Lyu X, Yang R. Screening of a Bacillus subtilis strain producing both nattokinase and milk-clotting enzyme and its application in fermented milk with thrombolytic activity. J Dairy Sci. 2021;104:9437. 10.3168/jds.2020-19756
- Gallelli G, Di Mizio G, Palleria C, Siniscalchi A, Rubino P, et al. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients. 2021;13. 10.3390/nu13062031
- Liu S, Zhu J, Liu C, Li J, Li Z, et al. Synthesis of sustained release/controlled release nanoparticles carrying nattokinase and their application in thrombolysis. Pharmazie. 2021;76:145. 10.1691/ph.2021.0155
- Hodis HN, Mack WJ, Meiselman HJ, Kalra V, Liebman H, et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clin Hemorheol Microcirc. 2021;78:339. 10.3233/CH-211147
- Wu H, Wang Y, Zhang Y, Xu F, Chen J, et al. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. Redox Biol. 2020;32:101500. 10.1016/j.redox.2020.101500
- Pan X, Liang P, Teng L, Ren Y, Peng J, et al. Study on molecular mechanisms of nattokinase in pharmacological action based on label-free liquid chromatography-tandem mass spectrometry. Food Sci Nutr. 2019;7:3185. 10.1002/fsn3.1157
- Wu C, Gao C, Lü S, Xu X, Wen N, et al. Construction of polylysine dendrimer nanocomposites carrying nattokinase and their application in thrombolysis. J Biomed Mater Res A. 2018;106:440. 10.1002/jbm.a.36232
- Ren NN, Chen HJ, Li Y, Mcgowan GW, Lin YG. [A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia]. Zhonghua Yi Xue Za Zhi. 2017;97:2038. 10.3760/cma.j.issn.0376-2491.2017.26.005
